Form 4: Aerovate Therapeutics Officer Dake Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Benjamin T. Dake, a key officer at Aerovate Therapeutics, executed stock options and sold shares according to a pre-arranged trading plan.
Summary
- On March 27, 2024, Benjamin T. Dake, President, Chief Operating Officer, and Secretary of Aerovate Therapeutics, exercised stock options to acquire 11,068 shares of common stock at a price of $10.61 per share.
- Simultaneously, Dake sold 11,068 shares of common stock at a weighted average price of $27.9652 per share, with individual sales ranging from $27.95 to $28.18.
- Following these transactions, Dake directly owns 1,291 shares of Aerovate Therapeutics common stock.
- The transactions were executed under a Rule 10b5-1 trading plan adopted on November 16, 2023.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to stock option exercises and sales under a pre-arranged plan. There's no indication of positive or negative news for the company.
Positives
- The transactions were executed under a pre-arranged 10b5-1 trading plan, suggesting they were not based on insider information.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. The use of a 10b5-1 trading plan is a common practice to allow insiders to sell shares without raising concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 2021-12-14 | Grant date of employee stock option for 58,000 shares. |
| 2022-01-14 | First installment of stock option vested. |
| 2023-11-16 | Date the Reporting Person adopted the Rule 10b5-1 trading plan. |
| 2024-03-27 | Date of stock option exercise and share sale. |
| 2031-12-13 | Expiration date of the stock option. |
| 2024-03-28 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.